The Week Ahead: Fed...
Health Care: Drugs
Arrowhead Research Corporation (ARWR: NASDAQ)
$3.85 -0.08 | -2.04%
06/04/12 - 10:57 AM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.89 | 0.58 | 0.98 |
| Price to Sales (TTM) | 798.20 | 4.62 | 1.42 |
| Price to Book (MRQ) | 3.60 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 4.61 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -3.60 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -3.90 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -89.40 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -52.20 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -27.37 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | -100.00 | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.30 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 1.40 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.17 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.19 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -1,596.67 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -238.40 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -65.90 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -104.00 | 2.20 | 2.50 |
| Return on Investment (TTM) | -92.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -129.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 969.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -232,127.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 0.00 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with ARWR
- Portfolio NameUser Type
- UserKJP 2012 Carbon Flash Fund
- Contributor8 Penny Stocks Get Delistin...
- UserWilliam T Blanchard - Medical
- UserCaroline
- UserSimon $9000
- Usertreneehill's pennies
- Userpeaka22 Portfolio 1
- Userkevin sweeney Portfolio 1
- UserWORLD FREE
- Userkeyon communications
Latest ARWR Headlines from TheStreet
- Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript) 05.08.12 | 12:05 am
- 6 Stocks Hitting New 52-Week Highs 11.10.11 | 01:11 pm
- 8 Penny Stocks Get Delisting Warning 01.04.11 | 07:01 am
- Arrowhead Research CEO Discusses F4Q2010 Results  Earnings Call Transcript 12.22.10 | 09:12 pm
- Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript 08.12.10 | 06:08 pm
- Mediacom, Jones Soda: Midday Volume Plays 06.01.10 | 10:06 am
- Arrowhead Research, Verenium: Early Volume Plays 03.22.10 | 07:03 am
- Amicas, Limelight: Early Volume Plays 12.28.09 | 07:12 am
- Thursday's Small-Cap Winners & Losers 06.20.07 | 01:06 am
- Friday's ETF Winners & Losers 06.20.07 | 01:06 am
Press Releases for ARWR
- Arrowhead Presents Data On DPC System At TIDES 2012 - Business Wire 05.22.12 | 07:05 am
- Arrowhead Reports Fiscal 2012 Second Quarter Financial Results - Business Wire 05.08.12 | 04:05 pm
- Arrowhead Research Corporation Acquires Alvos Therapeutics And Proprietary Library Of Targeting Peptides - Business Wire 04.11.12 | 07:04 am
- Arrowhead Releases White Paper On Hepatitis B Virus And Potential RNAi Treatment - Business Wire 03.07.12 | 07:03 am
- Arrowhead Research Corporation And Axolabs GmbH Enter Into Strategic Alliance And Master Services Agreement For RNAi Therapeutics - Business Wire 03.05.12 | 07:03 am
- Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1) - Business Wire 02.29.12 | 07:02 am
- Arrowhead Reports Fiscal 2012 First Quarter Financial Results - Business Wire 02.09.12 | 04:02 pm
- Arrowhead To Report Fiscal 2012 First Quarter Financial Results - Business Wire 02.02.12 | 07:02 am
- Alnylam And Arrowhead Form Collaboration And Licensing Agreement - Business Wire 01.05.12 | 08:01 am
- Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial - Business Wire 01.04.12 | 07:01 am
Partner Headlines for ARWR
- 4 Smaller Alternatives to Big Pharma Obesity Treatments - Benzinga 05.25.12 | 01:05 pm
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Arrowhead Reports Q1 EPS of $(0.02) - Benzinga 02.10.11 | 04:02 pm
- UPDATE 1-Arrowhead co, Smith & Nephew to make cartilage product - Reuters 10.18.10 | 08:10 am
